- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.04. | Acumen Pharmaceuticals, Inc.: Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting | 45 | GlobeNewswire (Europe) | Presentation and poster include deeper data insights on sabirnetug safety profile, target engagement and fluid biomarker changesPresentation to be featured during AAN Emerging Science SessionCompany... ► Artikel lesen | |
| 04.04. | Acumen Pharmaceuticals Signs Collaboration Agreement with Lonza | 116 | Contract Pharma | ||
| 04.04. | Acumen Pharmaceuticals partners with Lonza to advance sabirnetug for the treatment of Alzheimer's | 64 | Seeking Alpha | ||
| 04.04. | Acumen Pharma Partners Lonza To Advance Sabirnetug For Alzheimer's Disease Treatment | 56 | RTTNews | ||
| 04.04. | Acumen Pharmaceuticals, Inc.: Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer's Disease | 91 | GlobeNewswire (Europe) | Lonza to manufacture Acumen's monoclonal antibody, sabirnetug (ACU193), for clinical development and commercialization, if approvedSabirnetug is the first monoclonal antibody candidate to enter the... ► Artikel lesen | |
| 27.03. | Acumen Pharmaceuticals files for $200M mixed shelf offering | 2 | Seeking Alpha | ||
| 27.03. | Acumen Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 27.03. | Acumen Pharmaceuticals, Inc. (ABOS) Q4 2023 Earnings Call Transcript | 1 | Insider Monkey | ||
| 27.03. | Earnings call: Acumen Pharmaceuticals reports on Alzheimer's drug progress | 3 | Investing.com | ||
| 26.03. | Acumen Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary | 1 | Reuters | ||
| 26.03. | Acumen Pharmaceuticals, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 26.03. | Acumen Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 26.03. | Acumen Pharmaceuticals GAAP EPS of -$1.08 | 1 | Seeking Alpha | ||
| 26.03. | Acumen Pharmaceuticals, Inc.: Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights | 67 | GlobeNewswire (Europe) | Initiation of a Phase 2 study, ALTITUDE-AD, to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease expected in the first half of 2024 Initiation of a Phase 1 study to support... ► Artikel lesen | |
| 25.03. | Acumen Pharmaceuticals' Earnings: A Preview | 1 | Benzinga.com | ||
| 19.03. | Acumen Pharmaceuticals, Inc.: Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024 | 1 | GlobeNewswire (USA) | ||
| 19.03. | Acumen Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.03. | Acumen Pharmaceuticals, Inc.: Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days | 2 | GlobeNewswire (USA) | ||
| 08.03. | Acumen Pharmaceuticals, Inc.: Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD 2024 Annual Meeting | 106 | GlobeNewswire (Europe) | - Cerebrospinal fluid (CSF) biomarker results are highly supportive of sabirnetug's downstream pharmacological effects in the brain in early AD - Poster presentation showcases method used to develop... ► Artikel lesen | |
| 21.02. | Acumen Pharmaceuticals, Inc.: Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD 2024 Annual Meeting | 1 | GlobeNewswire (USA) |
Seite:
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,545 | -5,21 % | EQS-NVR: Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Epigenomics AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG... ► Artikel lesen | |
| BIOGEN | 194,95 | -0,18 % | Biogen Aktie: Druck auf Multiple-Sklerose-Markt | Das amerikanische Biotechnologieunternehmen Biogen Inc. steht kurz vor der Verkündigung seiner Quartalszahlen für das erste Quartal 2024 am 24. April. Analysten prognostizieren aufgrund erhöhten Wettbewerbsdrucks... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 0,780 | -1,39 % | Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates | Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates
In-depth analysis of VIVIAD Phase 2b results is ongoing, including pre-specified... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,860 | +1,18 % | Kaufen nach Abverkauf? Defence Therapeutics, Infineon Technologies, Super Micro Computer, TSMC Aktie | Die Marktteilnehmer waren nach den starken Kursrückgängen von Dow Jones und DAX sehr nervös. Schon panikartig wurden in der Nacht zu Freitag viele Aktien und damit auch Indizes abverkauft. Erst in den... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,860 | +10,30 % | Looking Into Ginkgo Bioworks Holdings' Recent Short Interest | ||
| DENALI THERAPEUTICS | 14,300 | -0,69 % | Biotech-Hoffnung Denali explodiert 38 Prozent: So sind Sie jetzt bei den Top-Trends der Branche ... | Mit einem Kursplus von 38 Prozent hat sich die Aktie des Biotech-Unternehmens Denali Therapeutics am Dienstag eindrucksvoll zurückgemeldet. Der Grund für den Kurssprung sind allerdings nicht Studiendaten... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,360 | -1,11 % | Expert Ratings For Beam Therapeutics | ||
| ONCOLYTICS BIOTECH | 1,010 | -1,94 % | Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting | SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology,... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,120 | +3,57 % | Recursion Pharmaceuticals' Options Frenzy: What You Need to Know | ||
| AC IMMUNE | 2,330 | +6,39 % | AC Immune verringert Verlust - wichtige Daten in der zweiten Jahreshälfte 2024 | Das Schweizer Biotech-Unternehmen AC Immune hat Zahlen für das Jahr 2023 vorgelegt. Mit einem Cash-Bestand von 103 Millionen Schweizer Franken zuzüglich 40 Millionen Schweizer Franken Meilensteinzahlungen... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 26,550 | +1,45 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 0,828 | +5,49 % | Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024 | ||
| SIGA TECHNOLOGIES | 8,790 | +1,74 % | SIGA Technologies - Positive signals abound | SIGA Technologies announced a strategic step in fortifying its distribution partner, Meridian, allowing greater control over planning and executing its international development efforts, a key growth... ► Artikel lesen | |
| MERRIMACK PHARMACEUTICALS | 14,730 | 0,00 % | Merrimack Pharmaceuticals, Inc. Reports Full Year 2023 Financial Results | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced its full year 2023 financial results for the period ended December... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 8,230 | +7,86 % | Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.
"Vir... ► Artikel lesen |
ACUMEN PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 3,170 Euro und damit -0,63 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
